We can't find the internet
Attempting to reconnect
18533.1 PFLS-LS
Development of next-generation antibody drug conjugates for the treatment of lung cancer and multiple myeloma
Résumé
Development of next-generation antibody drug conjugates for the treatment of lung cancer and multiple myeloma
Textes supplémentaires
Abstract
NBE-Therapeutics has developed novel next-generation homogeneous antibody drug conjugates (ADCs)|with proven efficacy in preclinical models of solid tumors, like lung and breast cancer, and hematological|tumors, particularly in multiple myeloma. The goal of the project is to generate optimized ADC lead candidates from early candidates which will be guided by a rigorous assessment of the developability profiles of the ADCs. It will include the development of advanced analytical assays and will lead to novel and optimized ADC candidates for clinical development.
Participants
Ulf Grawunder
Wirtschaftspartner
ulf.grawunder@nbe-therapeutics.com
NBE-Therapeutics GmbH Ulf Grawunder Hochbergerstr. 60C 4057 Basel BS CH
Christiane Zaborosch
Kontaktperson
christiane.zaborosch@zhaw.ch
ZHAW Christiane Zaborosch Einsiedlerstrasse 31 8820 Wädenswil ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2016-04-30
- Date de fin
- 2018-04-30
- Coûts totaux approuvés
- CHF 608800.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%